Tocilizumab supply improving
The Therapeutic Goods Administration (TGA) has advised that availability of tocilizumab (Actemra) in Australia continues to improve but will remain constrained throughout early 2022.
Following supply modelling and collaboration with TGA, the Australian Rheumatology Association and Arthritis Australia advises that the use of IV tocilizumab (Actemra) in some patient groups can now be increased.
However, as access to either subcutaneous presentation (ACTPen and pre-filled syringe) may still fluctuate, it is important to proceed with caution in usage of tocilizumab until supply is stable. To ensure all patients have continual access to subcutaneous tocilizumab (Actemra) as supply returns, the Serious Scarcity Substitution Instrument(link is external) (SSSI) remains in place until 30 April 2022.
Further information is available here.
